MitoGel

As Barrett steps in as CEO, UroGen reports 57% complete response rate for urothelial cancer therapy
BioCentury
Tue, 01/8/19 - 11:44 pm
Urogen
UGN-101
MitoGel
urothelial cancer
Liz Barrett